About one-third showed evidence of cognitive impairment.

The experts selected a control group of 80 people without ALS, matched to the ALS sufferers by age, education and gender, from a number of patients described a storage disorder clinic from 1992 to 2003. Of the 40 patients with ALS, 12 showed proof cognitive impairment, including nine who fulfilled requirements for dementia. There were no significant differences between ALS sufferers who got dementia and the ones who did not with regards to age, sex, education, site of onset, memory loss, emotional balance, severity of the family or disease history. ALS patients and control participants had similar results on cognitive tests, although patients with more severe ALS demonstrated a decline in verbal skills beyond what would be associated with motor complications affecting speech muscles.Norris, David Gosselin, Donna Reichart and Christopher K. Cup, all at UC San Diego. Funding support because of this research came, in part, from the National Institutes of Health .

Canada needs to modernize its pharmaceutical laws to ensure drug safety: CMAJ Canada needs to modernize its prescription laws to ensure that new drugs and also older drugs are safe and sound for Canadians, states an editorial in CMAJ Canadians are left inadequately protected by a federal government Food and Drugs Work that is clearly a dusty relic, virtually untouched since 1953, writes Dr. Paul H-bert, Editor-in-Chief, with coauthors. This leaves Wellness Canada with the Herculean job of making certain both old and brand-new medications are as secure because they are effective without the powers, regulatory tools or assets to do so.